DURHAM, N.C. (AP) _ BioCryst Pharmaceuticals Inc. (BCRX) on Tuesday reported a loss of $18.4 million in its second quarter.

On a per-share basis, the Durham, North Carolina-based company said it had a loss of 19 cents.

The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share.

The drugmaker posted revenue of $12.5 million in the period, which also topped Street forecasts. Three analysts surveyed by Zacks expected $3.8 million.

BioCryst shares have increased 19 percent since the beginning of the year. The stock has increased 15 percent in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BCRX at https://www.zacks.com/ap/BCRX